Emerging studies suggest Retatru tide , a dual activator targeting both incretin and another hormone, could represent a significant step forward for obesity treatment. Initial patient trials have shown impressive decreases in abdominal fat , potentially outperforming existing body composition therapies . However , more study is required to fully de